Healthcare Bearish Stocks: Mediwound (NASDAQ:MDWD), Five Star Quality Care (NYSE:FVE), Ventrus Biosciences (NASDAQ:VTUS), Tonix Pharmaceuticals Holding (NASDAQ:TNXP)

Technology Stocks News 3

Israeli-based MediWound Ltd (NASDAQ:MDWD) has developed a treatment to remove dead skin from burn wounds, and it has been approved by the European Medicines Agency. Mediwound Ltd (NASDAQ:MDWD) stock performance was -6.88% in last session and finished the day at $14.48. Traded volume was 485.2K shares in the last session and the average volume of the stock remained 1.40million shares.

Five Star Quality Care, Inc. (NYSE:FVE) was downgraded by investment analysts at JMP Securities from an “outperform” rating to a “market perform” rating in a note issued to investors on Thursday, American Banking & Market News reports. Five Star Quality Care, Inc. (NYSE:FVE) dropped -9.49 percent to $4.96 Thursday on volume of 603.00K shares. The intra-day range of the stock was $4.95 to $5.35. Five Star Quality Care, Inc. (NYSE:FVE) has a market capitalization of $241.15million.

Ventrus Biosciences Inc (NASDAQ:VTUS)’s shares jumped 2.94% to $1.40. The company on Feb. 12 announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). Ventrus Biosciences Inc (NASDAQ:VTUS)’s stock on Mar 27, 2014 reported a decrease of -5.26% to the closing price of $1.26. Its fifty two weeks range is $1.22 -$4.69. The total market capitalization recorded $26.28million. The overall volume in the last trading session was 764.00K shares. In its share capital, VTUS has 19.90million outstanding shares.

On March 3, 2014 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced that they had recently held a pre-Investigational New Drug (pre-IND) meeting with the US. Food and Drug Administration (FDA) to discuss the development of TNX-201, a single isomer isometheptene (IMH) for the relief of episodic tension-type headache (ETTH). On Thursday, shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) dropped -5.64% to close the day at $10.04. Company monthly performance is recorded as -29.49%. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) quarterly revenue growth is 0.40%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone